Genprex (NASDAQ:GNPX) Trading Down 2.4% – Should You Sell?

Genprex (NASDAQ:GNPX)’s share price fell 2.4% during trading on Tuesday . The stock traded as low as $1.99 and last traded at $2.02. 248,165 shares changed hands during trading, a decline of 79% from the average session volume of 1,202,952 shares. The stock had previously closed at $2.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Genprex Price Performance

The company’s 50 day moving average is $2.25 and its two-hundred day moving average is $5.42. The firm has a market cap of $6.31 million, a P/E ratio of -0.08 and a beta of -0.77.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP lifted its position in shares of Genprex (NASDAQ:GNPX) by 11.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent filing with the Securities and Exchange Commission. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.